Invasive Pulmonary Aspergillosis Clinical Trial
Official title:
Use of Voriconazole Inhalation Powder for the Treatment of Pulmonary Aspergillosis
Voriconazole Inhalation Powder is available on an expanded access basis to patients with pulmonary aspergillosis for up to 12 weeks. Duration of treatment may be extended on a case-by-case basis depending on drug availability and after discussion with the Sponsor.
The purpose of this expanded access protocol is to provide, upon the treating clinician's request and Sponsor assessment, Voriconazole Inhalation Powder to patients with pulmonary aspergillosis, or patients with other voriconazole-sensitive pulmonary fungal infections, who have limited or no other treatment options or who have had unfavorable response to adequate standard of care antifungal therapy including to oral or intravenous voriconazole. Reporting of serious adverse events (SAE) and Adverse Events of Special Interest (AESI) are required under this expanded access protocol. Patient treatment and outcomes information are also intended to be gathered under this protocol to the extent feasible (e.g., disease progression/improvement after treatment). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01782131 -
A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069)
|
Phase 3 | |
| Recruiting |
NCT05138666 -
Non-invasive Tools to Diagnose Invasive Aspergillosis Infections in ICU Patients With COVID-19 and Other Conditions.
|
N/A | |
| Not yet recruiting |
NCT02234739 -
Voriconazole for IPA in Chinese Patients With COPD
|
Phase 4 | |
| Completed |
NCT01615809 -
Nebulized Amphotericin B Lipid Complex in Invasive Pulmonary Aspergillosis in Paediatric Patients With Acute Leukaemia
|
Phase 2 | |
| Completed |
NCT04267497 -
Nebulised Liposomal Amphotericin for Invasive Pulmonary Aspergillosis (NAIFI01 Study)
|
Phase 1 | |
| Recruiting |
NCT05860387 -
Early Diagnosis of Invasive Lung Aspergillosis
|
||
| Withdrawn |
NCT01188759 -
Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects
|
Phase 3 | |
| Completed |
NCT00923832 -
Early Molecular Detection for the Improved Diagnosis of Invasive Pulmonary Aspergillosis and Invasive Pulmonary Zygomycosis
|
N/A | |
| Recruiting |
NCT05982912 -
VOC in Breath Samples for the Diagnosis of IPA
|
||
| Not yet recruiting |
NCT02100761 -
CYP 2C19 Polymorphism and Voriconazole Trough Concentration in Chinese Adult Patients
|
N/A | |
| Recruiting |
NCT00986713 -
Value of Amphotericin B Inhalation for Prophylaxis of Invasive Pulmonary Aspergillosis After Renal Transplantation
|
Phase 4 | |
| Recruiting |
NCT05569824 -
LFD of Aspergillus Antigen in Paediatrics
|
||
| Not yet recruiting |
NCT04848831 -
Diagnosis of Invasive Pulmonary Aspergillosis, Specific Testing in Bronchial Secretions Versus Bronchoalveolar Fluid
|
||
| Completed |
NCT04077697 -
Clinical and Prognostic Comparisons Between Invasive Pulmonary Aspergillosis With or Without Invasive Tracheobronchitis During Severe Influenza: a Retrospective Multicenter Cohort Study.
|
||
| Completed |
NCT03672292 -
Study to Evaluate the Safety and Efficacy of the Coadministration of Ibrexafungerp (SCY-078) With Voriconazole in Patients With Invasive Pulmonary Aspergillosis
|
Phase 2 | |
| Recruiting |
NCT01499433 -
Efficacy and Safety of Caspofungin for Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease
|
Phase 4 | |
| Completed |
NCT01247142 -
Evaluation of Exhaled Breath Condensate in the Diagnosis of Invasive Pulmonary Aspergillosis
|
N/A | |
| Completed |
NCT00501098 -
Prophylaxis of Fungal Invasive Infections in Leukemia
|
Phase 2 | |
| Recruiting |
NCT03748069 -
Influenza Associated Aspergillosis In-depth Investigation
|
||
| Completed |
NCT02058316 -
Bronchoalveolar Lavage Lateral-Flow Device Test for Invasive Pulmonary Aspergillosis: a Multicenter Study
|